52-Weel Range: $2.33-4.85 Approx. MktCap: $46 Million
Acurx At A Glance
Quick read covering Acurx’s Phase 2 program in C. diff and its potential to unseat vancomycin, the current standard of care, if late-stage studies confirm current data.
Acurx Pharmaceuticals is a publicly held, clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention, and Food and Drug Administration.
Acurx Corporate Presentation
Acurx Phase 2a Poster at ID Week
Acurx’s Phase 2a trial of ibezapolstat in C. diff was stopped early for success after 100 percent of the first 10 patients achieved clinical cure and didn’t relapse within the 28-day period after treatment ended.
Recent ASM Journal article details how beneficial changes suggestive of a lower risk of C. diff recurrence were associated with ibezapolstat compared to vancomycin.
American Society of Microbology
Visit Acurx's Website
Acurx's approach is to develop antibiotic candidates that block an entirely new molecular target previously unexploited in medical research, DNA polymerase IIIC (Pol IIIC). Its pipeline includes clinical stage and early stage antibiotic candidates that target Gram-positive bacteria for oral and/or parenteral treatment of infections caused by Clostridium difficile, Enterococcus (including vancomycin-resistant strains of VRE), Staphylococcus (including methicillin-resistant strains of MRSA), and Streptococcus (including antibiotic-resistant strains).
Important notice, please read: The information and statistical data contained herein may contain forward-looking statements that reflect the company’s intentions, expectations, assumptions, or beliefs concerning future events, including, but not limited to, expectations with respect to FDA and other regulatory bodies approval of new products, technology, and product development milestones, the ability of the company to leverage its product development and negotiate favorable collaborative agreements, the commencement of sales, the size of market opportunities with respect to the company’s product candidates and sufficiency of the company’s cash flow for future liquidity and capital resource needs and other risks identified in the Risk Factor Section of the company’s Annual Report on Form 10-K and any subsequent reports filed with the SEC. We do not undertake to advise you as to any change in this information. The forward-looking statements are qualified by important factors that could cause actual results to differ materially from those in the forward-looking statements. In addition, significant fluctuations in quarterly results may occur as a result of varying milestone payments and the timing of costs and expenses related to the company’s research and development programs. This is not a solicitation of any offer to buy or sell. Redington, Inc. is paid by subject company as an investor relations advisor, and its employees or members of their families may from time to time own an equity interest in companies mentioned herein.
